1-20 of 34
Amit M. Oza
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile

Ana C. Veneziani, Suku Sneha, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1434–1437.
https://doi.org/10.1158/1078-0432.CCR-23-3414
Published: 15 April 2024
View article titled, Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile
Open the PDF for Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile in another window
Journal Articles

Methodical Manipulation of the TME in Ovarian Cancer

Pamela Soberanis Pina, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 12–16.
https://doi.org/10.1158/1078-0432.CCR-23-2365
Published: 05 January 2024
View article titled, Methodical Manipulation of the TME in Ovarian Cancer
Open the PDF for Methodical Manipulation of the TME in Ovarian Cancer in another window
Journal Articles

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero, Peter Vuylsteke, Robert L. Coleman, Felix Hilpert, Amit M. Oza, Anneke Westermann, Martin K. Oehler, Sandro Pignata, Carol Aghajanian, Nicoletta Colombo, David Cibula, Kathleen N. Moore, Josep M. del Campo, Regina Berger, Christian Marth, Jalid Sehouli, David M. O'Malley, Cristina Churruca, Gunnar Kristensen, Andrew Clamp, John Farley, Gopa Iyer, Isabelle Ray-Coquard, Bradley J. Monk
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4068–4075.
https://doi.org/10.1158/1078-0432.CCR-23-0621
Published: 13 October 2023
View article titled, Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Open the PDF for Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stephanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo Gonzalez-Ochoa, Jeffrey P. Bruce, Derek Wong, Arnavaz Danesh, Dax Torti, Jonathan Torchia, Alexander Fortuna, Sharanjit Singh, Matthew Irving, Kayla Marsh, Bernard Lam, Vanessa Speers, Aleksandra Yosifova, Ana Oaknin, Ainhoa Madariaga, Neesha C. Dhani, Valerie Bowering, Amit M. Oza, Trevor J. Pugh
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3706–3716.
https://doi.org/10.1158/1078-0432.CCR-23-0797
Published: 15 September 2023
View article titled, Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Open the PDF for Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression in another window
Includes: Supplementary data
Journal Articles

Assessment of Homologous Recombination Deficiency in Ovarian Cancer

Vikas Garg, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 2957–2960.
https://doi.org/10.1158/1078-0432.CCR-23-0563
Published: 15 August 2023
View article titled, Assessment of Homologous Recombination Deficiency in Ovarian Cancer
Open the PDF for Assessment of Homologous Recombination Deficiency in Ovarian Cancer in another window
Journal Articles

Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial

Oliver Dorigo, Amit M. Oza, Tanja Pejovic, Prafull Ghatage, Sharad Ghamande, Diane Provencher, Lisa D. MacDonald, Heather Torrey, Valarmathy Kaliaperumal, Walead Ebrahimizadeh, Heather A. Hirsch, Yogesh Bramhecha, Jeannine Villella, Stephan Fiset
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2808–2815.
https://doi.org/10.1158/1078-0432.CCR-22-2595
Published: 01 August 2023
View article titled, Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial
Open the PDF for Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial in another window
Includes: Supplementary data
Journal Articles

An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer

Eduardo Gonzalez-Ochoa, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (14): 2563–2566.
https://doi.org/10.1158/1078-0432.CCR-23-0652
Published: 14 July 2023
View article titled, An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer
Open the PDF for An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer in another window
Journal Articles

Molecular Monitoring in Endometrial Cancer—Ready for Prime Time?

Brooke M. Grant, Trevor J. Pugh, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 305–308.
https://doi.org/10.1158/1078-0432.CCR-22-2781
Published: 17 January 2023
View article titled, Molecular Monitoring in Endometrial Cancer—Ready for Prime Time?
Open the PDF for Molecular Monitoring in Endometrial Cancer—Ready for Prime Time? in another window
Journal Articles

Taking the Road Less Traveled: Following Molecular Trail Markers

Ana C. Veneziani, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4357–4359.
https://doi.org/10.1158/1078-0432.CCR-22-1623
Published: 14 October 2022
View article titled, Taking the Road Less Traveled: Following Molecular Trail Markers
Open the PDF for Taking the Road Less Traveled: Following Molecular Trail Markers in another window
Journal Articles

Double Trouble: Whole-Genome Doubling Distinguishes Early from Late Ovarian Cancer

Shih Yu Cindy Yang, Trevor J. Pugh, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2730–2732.
https://doi.org/10.1158/1078-0432.CCR-22-0336
Published: 01 July 2022
View article titled, Double Trouble: Whole-Genome Doubling Distinguishes Early from Late Ovarian Cancer
Open the PDF for Double Trouble: Whole-Genome Doubling Distinguishes Early from Late Ovarian Cancer in another window
Journal Articles

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

Kathleen N. Moore, Setsuko K. Chambers, Erika P. Hamilton, Lee-may Chen, Amit M. Oza, Sharad A. Ghamande, Gottfried E. Konecny, Steven C. Plaxe, Daniel L. Spitz, Jill J.J. Geenen, Tiffany A. Troso-Sandoval, Janiel M. Cragun, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M. Mugundu, Zhongwu Lai, Juliann Chmielecki, Suzanne F. Jones, David R. Spigel, Karen A. Cadoo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 36–44.
https://doi.org/10.1158/1078-0432.CCR-21-0158
Published: 05 January 2022
View article titled, Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
Open the PDF for Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study in another window
Includes: Supplementary data
Journal Articles

Moving Beyond BRCA—Incorporating Molecular Assays into Ovarian Cancer Trials

Michelle McMullen, Katherine Karakasis, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5271–5273.
https://doi.org/10.1158/1078-0432.CCR-20-2429
Published: 15 October 2020
View article titled, Moving Beyond BRCA—Incorporating Molecular Assays into Ovarian Cancer Trials
Open the PDF for Moving Beyond BRCA—Incorporating Molecular Assays into Ovarian Cancer Trials in another window
Journal Articles

COVID-19 Testing in Patients with Cancer: Does One Size Fit All?

Ainhoa Madariaga, Michelle McMullen, Semira Sheikh, Rajat Kumar, Fei-Fei Liu, Camilla Zimmermann, Shahid Husain, Gelareh Zadeh, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4737–4742.
https://doi.org/10.1158/1078-0432.CCR-20-2224
Published: 15 September 2020
View article titled, COVID-19 Testing in Patients with Cancer: Does One Size Fit All?
Open the PDF for COVID-19 Testing in Patients with Cancer: Does One Size Fit All? in another window
Journal Articles

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

Amit M. Oza, Maria Estevez-Diz, Eva-Maria Grischke, Marcia Hall, Frederik Marmé, Diane Provencher, Denise Uyar, Johanne I. Weberpals, Robert M. Wenham, Naomi Laing, Michael Tracy, Tomoko Freshwater, Mark A. Lee, Ji Liu, Jingjun Qiu, Shelonitda Rose, Eric H. Rubin, Kathleen Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4767–4776.
https://doi.org/10.1158/1078-0432.CCR-20-0219
Published: 15 September 2020
View article titled, A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <em>TP53</em>-mutant Ovarian Cancer
Open the PDF for A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <em>TP53</em>-mutant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer

Taymaa May, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4432–4434.
https://doi.org/10.1158/1078-0432.CCR-20-1376
Published: 01 September 2020
View article titled, Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer
Open the PDF for Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer in another window
Journal Articles

EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

Stephanie Lheureux, Ana Oaknin, Swati Garg, Jeffrey P. Bruce, Ainhoa Madariaga, Neesha C. Dhani, Valerie Bowering, Justin White, Sarah Accardi, Qian Tan, Marsela Braunstein, Katherine Karakasis, Iulia Cirlan, Stephanie Pedersen, Tiantiam Li, Lorena Fariñas-Madrid, Yeh Chen Lee, Zhihui (Amy) Liu, Trevor J. Pugh, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4206–4215.
https://doi.org/10.1158/1078-0432.CCR-19-4121
Published: 14 August 2020
View article titled, EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Open the PDF for EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression in another window
Includes: Supplementary data
Journal Articles

Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines

Marc Tischkowitz, Sidong Huang, Susana Banerjee, Jennifer Hague, William P.D. Hendricks, David G. Huntsman, Jessica D. Lang, Krystal A. Orlando, Amit M. Oza, Patricia Pautier, Isabelle Ray-Coquard, Jeffrey M. Trent, Michael Witcher, Leora Witkowski, W. Glenn McCluggage, Douglas A. Levine, William D. Foulkes, Bernard E. Weissman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3908–3917.
https://doi.org/10.1158/1078-0432.CCR-19-3797
Published: 03 August 2020
View article titled, Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines
Open the PDF for Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines in another window
Journal Articles

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)

Neesha C. Dhani, Hal W. Hirte, Lisa Wang, Julia V. Burnier, Angela Jain, Marcus O. Butler, Stephen Welch, Gini F. Fleming, Jean Hurteau, Koji Matsuo, Daniela Matei, Waldo Jimenez, Carolyn Johnston, Mihaela Cristea, Katia Tonkin, Prafull Ghatage, Stephanie Lheureux, Anjali Mehta, Judy Quintos, Qian Tan, Suzanne Kamel-Reid, Olga Ludkovski, Ming-Sound Tsao, John J. Wright, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2477–2486.
https://doi.org/10.1158/1078-0432.CCR-19-2576
Published: 01 June 2020
View article titled, Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Open the PDF for Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86) in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Amit M. Oza, Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, William P. McGuire, Sharad Ghamande, Michael J. Birrer, Gini F. Fleming, Merry Jennifer Markham, Hal W. Hirte, Diane M. Provencher, Bristi Basu, Rebecca Kristeleit, Deborah K. Armstrong, Benjamin Schwartz, Patricia Braly, Geoff D. Hall, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Yong Hao, Harold Keer, Mohammad Azab, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1009–1016.
https://doi.org/10.1158/1078-0432.CCR-19-1638
Published: 02 March 2020
View article titled, A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Open the PDF for A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?

Ainhoa Madariaga, Pamela J. Goodwin, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 523–525.
https://doi.org/10.1158/1078-0432.CCR-19-3645
Published: 03 February 2020
View article titled, Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?
Open the PDF for Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment? in another window